Skip to content

Nasdaq · CIK 0001854270

SNTI Senti Biosciences, Inc.

Insider trading from SEC Form 4. Last filing Jul 21, 2025.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company

Signals

Open-market buys and sells at Senti Biosciences, Inc., scored.

No scored open-market trades yet. Grants, exercises and other rows are below.

Transactions

The last 23 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Jul 18, 2025Bryan Daniel Baum
director
AGrant or award
Stock Option (Right to Buy)derivative
+43,900$0.00$043,900Jul 21, 2025
Jun 25, 2025Brenda Cooperstone
director
AGrant or award
Stock Option (Right to Buy)derivative
+21,950$0.00$021,950Jun 27, 2025
Jun 25, 2025James J. Collins
director
AGrant or award
Stock Option (Right to Buy)derivative
+21,950$0.00$021,950Jun 27, 2025
Jun 25, 2025Feng Hsiung
director
AGrant or award
Stock Option (Right to Buy)derivative
+21,950$0.00$021,950Jun 27, 2025
Jun 25, 2025Edward T Mathers
director
AGrant or award
Stock Option (Right to Buy)derivative
+21,950$0.00$021,950Jun 27, 2025
Jun 25, 2025Fran Schulz
director
AGrant or award
Stock Option (Right to Buy)derivative
+21,950$0.00$021,950Jun 27, 2025
Jun 25, 2025Donald F Tang
director
AGrant or award
Stock Option (Right to Buy)derivative
+21,950$0.00$021,950Jun 27, 2025
Mar 10, 2025Celadon Partners SPV 24
owner
CConversion
Common Stock
+9,777,000--9,777,000Mar 14, 2025
Mar 10, 2025Celadon Partners SPV 24
owner
CConversion
Series A Convertible Preferred Stockderivative
-9,777--0Mar 14, 2025
Mar 10, 2025Bayer Healthcare LLC
owner
CConversion
Common Stock
+2,222,000--2,809,848Mar 12, 2025
Mar 10, 2025New Enterprise Associates 15, L.P.
owner
CConversion
Common Stock
+3,333,000--3,775,615Mar 12, 2025
Mar 10, 2025New Enterprise Associates 15, L.P.
owner
CConversion
Series A Convertible Preferred Stockderivative
-3,333--0Mar 12, 2025
Mar 10, 2025Bayer Healthcare LLC
owner
CConversion
Series A Convertible Preferred Stockderivative
-2,222--0Mar 12, 2025
Mar 7, 2025Brenda Cooperstone
director
AGrant or award
Stock Option (Right to Buy)derivative
+43,900$0.00$043,900Mar 11, 2025
Mar 7, 2025James J. Collins
director
AGrant or award
Stock Option (Right to Buy)derivative
+43,900$0.00$043,900Mar 11, 2025
Mar 7, 2025John Harry Cross III
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+174,200$0.00$0174,200Mar 11, 2025
Mar 7, 2025Feng Hsiung
director
AGrant or award
Stock Option (Right to Buy)derivative
+43,900$0.00$043,900Mar 11, 2025
Dec 9, 2024Bayer Healthcare LLC
owner
POpen-market purchase
Series A Convertible Preferred Stockderivative
+2,222--2,222Dec 11, 2024
Dec 9, 2024Bayer Healthcare LLC
owner
POpen-market purchase
Warrantderivative
+3,333,000--3,330,000Dec 11, 2024
Dec 9, 2024Kanya Rajangam
Pres. & Chief Med. & Dev. Off.
AGrant or award
Series A Convertible Preferred Stockderivativeindirect: Iyer Family Revocable Trust dated Aug 26 2012
+33$2,250.00$74k33Dec 10, 2024
Dec 9, 2024Fran Schulz
director
AGrant or award
Stock Option (Right to Buy)derivative
+12,500$0.00$012,500Dec 10, 2024
Dec 9, 2024Donald F Tang
director
AGrant or award
Stock Option (Right to Buy)derivative
+12,500$0.00$012,500Dec 10, 2024
Dec 9, 2024Kanya Rajangam
Pres. & Chief Med. & Dev. Off.
AGrant or award
Common Stock Warrant (right to buy)derivativeindirect: Iyer Family Revocable Trust dated Aug 26 2012
+49,500$0.00$049,500Dec 10, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

SNTI insider trading: Senti Biosciences, Inc. | InsiderTell